Stomach dysfunction in diabetes mellitus: Emerging technology and pharmacology

Journal of Diabetes Science and Technology

Volumn 4, Issue 1, 2010, Pages 180-189

  Szarka, Lawrence A ^a   Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

Diabetes; Gastric emptying; Gastroparesis; Stomach; Therapeutics

Indexed keywords

BARIATRIC SURGERY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIGESTIVE SYSTEM EXAMINATION; DRUG THERAPY; ELECTROSTIMULATION; GASTROINTESTINAL MOTILITY; HUMAN; METHODOLOGY; PATHOPHYSIOLOGY; PHARMACOLOGY; PHYSIOLOGY; REVIEW; STOMACH DISEASE; STOMACH PARESIS;

BARIATRIC SURGERY; DIABETES COMPLICATIONS; DIABETIC NEUROPATHIES; DIAGNOSTIC TECHNIQUES, DIGESTIVE SYSTEM; DRUG THERAPY; ELECTRIC STIMULATION; GASTROINTESTINAL MOTILITY; GASTROPARESIS; HUMANS; PHARMACOLOGY; STOMACH DISEASES;

EID: 77954683730     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400123     Document Type: Review

References (85)

1. Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998;43(11):2398-404.
2. Hoogerwerf WA, Pasricha PJ, Kalloo AN, Schuster MM. Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol. 1999;94(4):1029-33.
3. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001;24(7):1264-9.
4. Delgado-Aros S, Camilleri M, Castillo EJ, Cremonini F, Stephens D, Ferber I, Baxter K, Burton D, Zinsmeister AR. Effect of gastric volume or emptying on meal-related symptoms after liquid nutrients in obesity: a pharmacologic study. Clin Gastroenterol Hepatol. 2005;3(10):997-1006.
5. Delgado-Aros S, Camilleri M, Cremonini F, Ferber I, Stephens D, Burton DD. Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology. 2004;127(6):1685-94.
6. Bredenoord AJ, Chial HJ, Camilleri M, Mullan BP, Murray JA. Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol. 2003;1(4):264-72.
7. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 2001;24(2):371-81.
8. Maleki D, Locke GR 3rd, Camilleri M, Zinsmeister AR, Yawn BP, Leibson C, Melton LJ 3rd. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med. 2000;160(18):2808-16.
9. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161(16):1989-96.
10. Nowak TV, Johnson CP, Kalbfleisch JH, Roza AM, Wood CM, Weisbruch JP, Soergel KH. Highly variable gastric emptying in patients with insulin dependent diabetes mellitus. Gut. 1995;37(1):23-9.
11. Kong MF, Horowitz M, Jones KL, Wishart JM, Harding PE. Natural history of diabetic gastroparesis. Diabetes Care. 1999;22(3):503-7.
12. Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med. 2007;356(8):820-9.
13. Hyett B, Martinez FJ, Gill BM, Mehra S, Lembo A, Kelly CP, Leffler DA. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology. 2009;137(2)445-52.
14. Jung HK, Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Szarka LA, Mullan B, Talley NJ. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136(4):1225-33.
15. Szarka LA, Camilleri M. Methods for measurement of gastric motility. Am J Physiol Gastrointest Liver Physiol. 2009;296(3):G461-75.
16. Camilleri M, Hasler WL, Parkman HP, Quigley EM, Soffer E. Measurement of gastrointestinal motility in the GI laboratory. Gastroenterology. 1998;115(3):747-62.
17. Akkermans LM, van Isselt JW. Gastric motility and emptying studies with radionuclides in research and clinical settings. Dig Dis Sci. 1994;39(12 Suppl):95S-6S.
18. Loo FD, Palmer DW, Soergel KH, Kalbfleisch JH, Wood CM. Gastric emptying in patients with diabetes mellitus. Gastroenterology. 1984;86(3):485-94.
19. Abell TL, Camilleri M, Donohoe K, Hasler WL, Lin HC, Maurer AH, McCallum RW, Nowak T, Nusynowitz ML, Parkman HP, Shreve P, Szarka LA, Snape WJ Jr, Ziessman HA, American Neurogastroenterology and Motility Society, Society of Nuclear Medicine. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol. 2008;103(3):753-63.
20. Tougas G, Eaker EY, Abell TL, Abrahamsson H, Boivin M, Chen J, Hocking MP, Quigley EM, Koch KL, Tokayer AZ, Stanghellini V, Chen Y, Huizinga JD, Rydén J, Bourgeois I, McCallum RW. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol. 2000;95(6):1456-62.
21. Degen LP, Phillips SF. Variability of gastrointestinal transit in healthy women and men. Gut. 1996;39(2):299-305.
22. .Talley NJ, Locke GR 3rd, Lahr BD, Zinsmeister AR, Tougas G, Ligozio G, Rojavin MA, Tack J. Functional dyspepsia, delayed gastric emptying, and impaired quality of life. Gut. 2006;55(7):933-9.
23. .Viramontes BE, Kim DY, Camilleri M, Lee JS, Stephens D, Burton DD, Thomforde GM, Klein PD, Zinsmeister AR. Validation of a stable isotope gastric emptying test for normal accelerated or delayed gastric emptying. Neurogastroenterol Motil. 2001;13(6):567-74.
24. Szarka LA, Camilleri M, Vella A, Burton D, Baxter K, Simonson J, Zinsmeister AR. A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol. 2008;6(6):635-43.
25. Van de Casteele M, Luypaerts A, Geypens B, Fevery J, Ghoos Y, Nevens F. Oxidative breakdown of octanoic acid is maintained in patients with cirrhosis despite advanced disease. Neurogastroenterol Motil. 2003;15(2):113-20.
26. Kuo B, McCallum RW, Koch KL, Sitrin MD, Wo JM, Chey WD, Hasler WL, Lackner JM, Katz LA, Semler JR, Wilding GE, Parkman HP. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther. 2008;27(2):186-96.
27. Cassilly D, Kantor S, Knight LC, Maurer AH, Fisher RS, Semler J, Parkman HP. Gastric emptying of a non-digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy. Neurogastroenterol Motil. 2008;20(4):311-9.
28. Schwizer W, Fraser R, Maecke H, Siebold K, Funck R, Fried M. Gd-DOTA as a gastrointestinal contrast agent for gastric emptying measurements with MRI. Magn Reson Med. 1994;31(4):388-93.
29. Kunz P, Crelier GR, Schwizer W, Borovicka J, Kreiss C, Fried M, Boesiger P. Gastric emptying and motility: assessment with MR imaging - preliminary observations. Radiology. 1998;207(1):33-40.
30. Borovicka J, Lehmann R, Kunz P, Fraser R, Kreiss C, Crelier G, Boesiger P, Spinas GA, Fried M, Schwizer W. Evaluation of gastric emptying and motility in diabetic gastroparesis with magnetic resonance imaging: effects of cisapride. Am J Gastroenterol. 1999;94(10):2866-73.
31. Lauenstein TC, Vogt FM, Herborn CU, DeGreiff A, Debatin JF, Holtmann G. Time-resolved three-dimensional MR imaging of gastric emptying modified by IV administration of erythromycin. Am J Roentgenol. 2003;180(5):1305-10.
32. Bilecen D, Scheffler K, Seifritz E, Bongartz G, Steinbrich W. Hydro-MRI for the visualization of gastric wall motility using RARE magnetic resonance imaging sequences. Abdom Imaging. 2000;25(1):30-4.
33. Fidler J, Bharucha AE, Camilleri M, Camp J, Burton D, Grimm R, Riederer SJ, Robb RA, Zinsmeister AR. Application of magnetic resonance imaging to measure fasting and postprandial volumes in humans. Neurogastroenterol Motil. 2009;21(1):42-51.
34. Bouras EP, Delgado-Aros S, Camilleri M, Castillo EJ, Burton DD, Thomforde GM, Chial HJ. SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography. Gut. 2002;51(6):781-6.
35. Delgado-Aros S, Burton DD, Brinkmann BH, Camilleri M. Reliability of a semi-automated analysis to measure gastric accommodation using SPECT in humans. Gastroenterology. 2001;120:A287.
36. De Schepper H, Camilleri M, Cremonini F, Foxx-Orenstein A, Burton D. Comparison of gastric volumes in response to isocaloric liquid and mixed meals in humans. Neurogastroenterol Motil. 2004;16(5):567-73.
37. Gilja OH, Hausken T, Odegaard S, Berstad A. Monitoring postprandial size of the proximal stomach by ultrasonography. J Ultrasound Med. 1995;14(2):81-9.
38. Liao D, Gregersen H, Hausken T, Gilja OH, Mundt M, Kassab G. Analysis of surface geometry of the human stomach using realtime 3-D ultrasonography in vivo. Neurogastroenterol Motil. 2004;16(3):315-24.
39. Manini ML, Burton DD, Meixner DD, Eckert DJ, Callstrom M, Schmit G, El-Youssef M, Camilleri M. Feasibility and application of 3-dimensional ultrasound for measurement of gastric volumes in healthy adults and adolescents. J Pediatr Gastroenterol Nutr. 2009;48(3):287-93.
40. Azpiroz F, Malagelada JR. Gastric tone measured by an electronic barostat in health and postsurgical gastroparesis. Gastroenterology. 1987;92(4):934-43.
41. Abell TL, Bernstein RK, Cutts T, Farrugia G, Forster J, Hasler WL, McCallum RW, Olden KW, Parkman HP, Parrish CR, Pasricha PJ, Prather CM, Soffer EE, Twillman R, Vinik AI. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil. 2006;18(4):263-83.
42. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339(2):69-75.
43. Kendall DM, Rooney DP, Smets YF, Salazar Bolding L, Robertson RP. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type I diabetes and autonomic neuropathy. Diabetes. 1997;46(2):249-57.
44. Solders G, Tydén G, Persson A, Groth CG. Improvement of nerve conduction in diabetic neuropathy. A follow-up study 4 yr after combined pancreatic and renal transplantation. Diabetes. 1992;41(8):946-51.
45. Cashion AK, Holmes SL, Hathaway DK, Gaber AO. Gastroparesis following kidney/pancreas transplant. Clin Transplant. 2004;18(3):306-11.
46. Salehi M, Aulinger BA, D'Alessio DA. Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev. 2008;29(3):367-79.
47. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA, Camilleri M. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 2007;56(5):1475-80.
48. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug insight: from disturbed motility to disordered movement - a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3(3):138-48.
49. Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008;48(3):379-84.
50. McCallum RW, Ricci DA, Rakatansky H, Behar J, Rhodes JB, Salen G, Deren J, Ippoliti A, Olsen HW, Falchuk K. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6(5):463-7.
51. Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94(5):1230-4.
52. Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol. 1997;92(6):976-80.
53. Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, Muls E, Bouillon R. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med. 1990;322(15):1028-31.
54. Chen CC, Lin CS, Ko YP, Hung YC, Lao HC, Hsu YW. Premedication with mirtazapine reduces preoperative anxiety and postoperative nausea and vomiting. Anesth Analg. 2008;106(1):109-13.
55. Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care. 2007;16(4):351-4.
56. Talley SJ, Bytzer P, Hammer J, Young L, Jones M, Horowitz M. Psychological distress is linked to gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol. 2001;96(4):1033-8.
57. Kim SW, Shin IS, Kim JM, Kang HC, Mun JU, Yang SJ, Yoon JS. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics. 2006;47(5):440-2.
58. De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20(2):99-112.
59. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120(2):354-60.
60. Camilleri M. Functional dyspepsia: mechanisms of symptom generation and appropriate management of patients. Gastroenterol Clin North Am. 2007;36(3):649-64.
61. Perkel MS, Moore C, Hersh T, Davidson ED. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig Dis Sci. 1979;24(9):662-6.
62. McCallum RW, Ricci DA, Rakatansky H, Behar J, Rhodes JB, Salen G, Deren J, Ippoliti A, Olsen HW, Falchuk K. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6(5):463-7.
63. Champion MC, Gulenchyn K, O'Leary T, Irvine P, Edwards A, Braaten J, Gay J. Domperidone (motilium) improves symptoms and solid phase gastric emptying in diabetic gastroparesis. Am J Gastroenterol. 1987;82:975-80.
64. Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol. 1997;92(6):976-80.
65. Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EM, McCallum R, Leidy NK, Farup C, Liu Y, Joslyn A, DOM-USA-5 Study Group. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. Clin Ther. 1998;20(3):438-53.
66. Franzese A, Borrelli O, Corrado G, Rea P, Di Nardo G, Grandinetti AL, Dito L, Cucchiara S. Domperidone is more effective than cisapride in children with diabetic gastroparesis. Aliment Pharmacol Ther. 2002;16(5):951-7.
67. Camilleri M, Kerstens R, Beyens G, Robinson P, Vandeplassche L. A double-blind, placebo-controlled trial to evaluate the safety and tolerability of prucalopride oral solution in constipated elderly patients living in a nursing facility. Gastroenterology. 2009;136(Suppl 1):240.
68. Camilleri M, Vazquez-Roque MI, Burton D, Ford T, McKinzie S, Zinsmeister AR, Druzgala P. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil. 2007;19(1):30-8.
69. Smith JA, Beattie DT, Marquess D, Shaw JP, Vickery RG, Humphrey PP. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(1):125-37.
70. Beattie DT, Armstrong SR, Shaw JP, Marquess D, Sandlund C, Smith JA, Taylor JA, Humphrey PP. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(1):139-47.
71. Manini ML, Camilleri M, Goldberg M, Sweetser S, McKinzie S, Burton D, Wong S, Kitt MM, Li YP, Zinsmeister AR. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil. 2009. [Epub ahead of print.]
72. Camilleri M, Papathanasopoulos A, Odunsi ST. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol. 2009;6(6):343-52.
73. Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008;103(2):416-23.
74. Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol. 2003;98(10):2122-9.
75. Kim CH, Nelson DK. Venting percutaneous gastrostomy in the treatment of refractory idiopathic gastroparesis. Gastrointest Endosc. 1998;47(1):67-70.
76. Michaud L, Guimber D, Carpentier B, Sfeir R, Lambilliotte A, Mazingue F, Gottrand F, Turck D. Gastrostomy as a decompression technique in children with chronic gastrointestinal obstruction. J Pediatr Gastroenterol Nutr. 2001;32(1):82-5.
77. Maple JT, Petersen BT, Baron TH, Harewood GC, Johnson CD, Schmit GD. Abdominal CT as a predictor of outcome before attempted direct percutaneous endoscopic jejunostomy. Gastrointest Endosc. 2006;63(3):424-30.
78. Lin Z, Sarosiek I, Forster J, McCallum RW. Symptom responses, long-term outcomes and adverse events beyond 3 years of high-frequency gastric electrical stimulation for gastroparesis. Neurogastroenterol Motil. 2006;18(1):18-27.
79. Lin Z, McElhinney C, Sarosiek I, Forster J, McCallum R. Chronic gastric electrical stimulation for gastroparesis reduces the use of prokinetic and/or antiemetic medications and the need for hospitalizations. Dig Dis Sci. 2005;50(7):1328-34.
80. .Abell T, McCallum R, Hocking M, Koch K, Abrahamsson H, Leblanc I, Lindberg G, Konturek J, Nowak T, Quigley EM, Tougas G, Starkebaum W. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology. 2003;125(2):421-8.
81. McCallum R, Brody FJ, Parkman HP, Wo JM, Nowak TV, Snape WJ, Lerew DR, Ruehlow L, Sarosiek I. Enterra® gastric electrical stimulation for diabetic gastroparesis: results from a multicenter randomized study. Gastroenterology. 2009;136(Suppl 1):376.
82. Xing J, Brody F, Rosen M, Chen JD, Soffer E. The effect of gastric electrical stimulation on canine gastric slow waves. Am J Physiol Gastrointest Liver Physiol. 2003;284(6):G956-62.
83. Lin Z, Forster J, Sarosiek I, McCallum R. Efficiency of two-channel gastric electrical pacing for entrainment of gastric slow waves. Gastroenterology. 2009;136(Suppl 1):W2042.
84. Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol. 2003;98(10):2122-9.
85. Camilleri M. The stomach in diabetes: from villain to ally. Clin Gastroenterol Hepatol. 2009;7(3):285-7.